DALE MICHAEL D

September 28, 2026

CVRx Appoints John Landry as CFO. CVRx announced that John Landry will become chief financial officer, effective Oct. 12, replacing Jared Oasheim. The change follows a routine leadership transition and may bring new financial oversight to the company. The appointment is noted by market watchers but does not alter the current trading range or technical signals. Investors can monitor how the new CFO’s approach aligns with the company’s financial goals.

October 12, 2026

Axogen Receives New Analyst Coverage and Valuation Upside. Axogen has attracted new analyst coverage from Robinhood and B of A Securities, both issuing bullish notes and setting price targets around $52. A Yahoo analysis suggests the stock may be about 26% undervalued on cash‑flow grounds, while the company has fallen 22.6% in the past month. These developments highlight renewed investor interest and potential upside relative to recent price action.

October 16, 2026

Abbott Labs launches Ensure Max Protein as earnings preview approaches. Abbott Laboratories introduced a new high‑protein nutritional drink, Ensure Max Protein, expanding its consumer health lineup. At the same time, investors are looking ahead to the company's third‑quarter earnings, with analysts focusing on revenue and earnings per share estimates. TD Cowen reaffirmed its positive view of Abbott, keeping a $135 price target, which aligns with the analyst consensus range. The stock is currently near a long‑standing support level around $99.90.